Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
clinical trials
life sciences
national blog main
san diego blog main
5
×
biotech
boston blog main
boston top stories
new york blog main
san diego top stories
fda
national top stories
boston
drugs
dyne therapeutics
myotonic dystrophy type 1
new york top stories
rare disease drugs
san francisco blog main
achaogen
adams street partners
akcea therapeutics
alder biopharmaceuticals
amgen
antibiotics
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
biotech ipos
bluebird bio
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
cardiomyopathy
chronic migraine
david rind
deals
What
drug
5
×
medicines
5
×
genetic
rare
therapeutics
ago
company
disease
dyne
fda
ipo
muscle
year
akcea
alnylam
amgen
amyloidosis
approval
approved
attr
available
bacteria
battle
biopharma
biotechs
brings
business
candidates
class
considering
data
debilitating
developed
developing
diseases
disorders
dyne’s
early
exited
expected
Language
unset
Current search:
medicines
×
photo
×
drug
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines